The effectiveness of AI applications can be undermined by the volumes of unstructured data prevalent in the pharma industry. What can be done to overcome this issue?
Artificial Intelligence company BenevolentAI has bought a drug discovery and development facility at the Babraham Research Campus in Cambridge for an undisclosed sum.